UroGen Pharma (NASDAQ:URGN) reported its Q3 earnings results on Tuesday, November 14, 2023 at 08:00 AM.
Here’s what investors need to know about the announcement.
Earnings
UroGen Pharma beat estimated earnings by 20.0%, reporting an EPS of $-0.68 versus an estimate of $-0.85.
Revenue was up $4.75 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.11 which was followed by a 4.48% increase in the share price the next day.
Here’s a look at UroGen Pharma’s past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.14 | -1.33 | -1.07 | -1.16 |
| EPS Actual | -1.03 | -1.30 | -1.22 | -1.13 |
| Revenue Estimate | 20.12M | 17.18M | 18.51M | 20.15M |
| Revenue Actual | 21.14M | 17.19M | 18.09M | 16.10M |
To track all earnings releases for UroGen Pharma visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
